US20210052516A1 - Method for increasing akkermansia in intestinal bacterial flora by ingesting astaxanthin - Google Patents
Method for increasing akkermansia in intestinal bacterial flora by ingesting astaxanthin Download PDFInfo
- Publication number
- US20210052516A1 US20210052516A1 US17/080,118 US202017080118A US2021052516A1 US 20210052516 A1 US20210052516 A1 US 20210052516A1 US 202017080118 A US202017080118 A US 202017080118A US 2021052516 A1 US2021052516 A1 US 2021052516A1
- Authority
- US
- United States
- Prior art keywords
- astaxanthin
- blood
- akkermansia
- intestinal bacterial
- bacterial flora
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 102
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 102
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 102
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 102
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 102
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 25
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 21
- 241000702460 Akkermansia Species 0.000 title claims abstract description 16
- 230000001965 increasing effect Effects 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 241000894006 Bacteria Species 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 241000702462 Akkermansia muciniphila Species 0.000 claims description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 241001112696 Clostridia Species 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 17
- 241000283984 Rodentia Species 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 12
- 241000168525 Haematococcus Species 0.000 description 11
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 3
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 241000305071 Enterobacterales Species 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 3
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- -1 Capsaicin (Shen W Chemical class 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000168517 Haematococcus lacustris Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000020237 cranberry extract Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- GIRXTOSJOKKBHO-BQTUIHPCSA-N food orange 7 Chemical compound CCOC(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C GIRXTOSJOKKBHO-BQTUIHPCSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002414 procyanidin Polymers 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010038851 tannase Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- DFMMVLFMMAQXHZ-DOKBYWHISA-N 8'-apo-beta,psi-caroten-8'-al Chemical compound O=CC(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C DFMMVLFMMAQXHZ-DOKBYWHISA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000206486 Adonis Species 0.000 description 1
- 240000006617 Agave salmiana Species 0.000 description 1
- 235000001619 Agave salmiana Nutrition 0.000 description 1
- 241000061154 Brevundimonas sp. Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DFMMVLFMMAQXHZ-IZEVWJMWSA-N E 160e Natural products CC(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)/C)C=O DFMMVLFMMAQXHZ-IZEVWJMWSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000190842 Erythrobacter sp. Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241001657434 Gordonia sp. Species 0.000 description 1
- 241000733385 Haematococcus capensis Species 0.000 description 1
- 241000500726 Haematococcus droebakensis Species 0.000 description 1
- 241000500309 Haematococcus zimbabwiensis Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001491666 Labyrinthulomycetes Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 241000589598 Paracoccus sp. Species 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000598397 Schizochytrium sp. Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 244000070384 Vitis labrusca Species 0.000 description 1
- 235000004282 Vitis labrusca Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 235000013970 phaffia yeast Nutrition 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 125000000264 xanthophyll group Chemical group 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention relates to a method for improving bacteria belonging to the genus Akkermansia in an intestinal bacterial flora, and the like.
- the intestinal bacterial flora changes depending on factors such as living environment and is believed to have a great impact on, for example, health status.
- IBS irritable bowel syndrome
- IBS central nervous function
- gastrointestinal function specifically, gut-brain interaction and hypersensitive gastrointestinal tract in the context of psychological stress.
- enterobacteria greatly influence obesity and a disease associated therewith.
- Akkermansia muciniphila enterobacteria are associated with obesity and a disease associated therewith.
- the present inventors investigated how astaxanthin influenced the intestinal bacterial flora and consequently accomplished the present invention.
- Japanese Patent Laid-Open No. H09-124470 discloses an anti-stress composition containing astaxanthin and/or an ester thereof as an active ingredient; however it does not disclose the influence of the composition on the intestinal bacterial flora in any way.
- a feature of an aspect of the present invention is inclusion of a step of ingesting a composition containing astaxanthin.
- FIG. 1 shows the result of comparison of intestinal bacterial floras
- FIGS. 2A and 2B show the result of a comparative study of increases in body weight
- FIG. 3 shows comparison of blood astaxanthin concentrations between a rodent and a human
- FIG. 4A shows the change in the astaxanthin concentration in human blood caused by continuous ingestion of astaxanthin; and FIG. 4B shows the measured data.
- An embodiment of the present invention includes the step of ingesting a composition containing astaxanthin for increasing bacteria belonging to the genus Akkermansia in the intestinal bacterial flora, preferably Akkermansia muciniphila among others.
- Astaxanthin is a type of carotenoid. Carotenoids are classified into carotenes and xanthophylls, and astaxanthin belongs to the xanthophyll group.
- astaxanthin is 3,3′-dihydroxy- ⁇ , ⁇ -carotene-4,4′-dione and there are three forms of astaxanthin depending on the configurations of the hydroxy groups at 3 and 3′ positions: a (3R,3′R) form, a (3R,3′S) form, and a (3S,3′S) form.
- Astaxanthin also has isomers defined by a cis-trans orientation around a conjugated double bond, and exists in a free form, a monoesterified form, or a diesterified form.
- Astaxanthin is known to have an antioxidative activity and it has low absorption efficiency, with its absorption percentage in the intestine being about 5%.
- 6-week-old Wistar rats were used to compare the intestinal bacterial floras of a group fed with an astaxanthin-containing diet for four weeks and a group fed with a normal diet for four weeks. It is presumed from the result that the number of Akkermansia muciniphila , bacteria of the genus Akkermansia , in the group fed with the astaxanthin-containing diet increased and is about 11.7 times higher than that of the group fed with the normal diet.
- saponin (Leal-Diaz A M, Noriega L G, Torre-Villalvazo I, Torres N, Aleman-Escondrillas G, Lopez-Romero P, Sanchez-Tapia M, Aguilar-Lopez M, Furuzawa-Carballeda J, Velazquez-Villegas L A, Avila-Nava A, Ordaz G, Gutierrez-Uribe J A, Serna-Saldivar S O, Tovar A R.
- Cranberry extract (Anhe F F, Roy D, Pilon G, Dudonne S, Matamoros S, Varin T V, Garofalo C, Moine Q, Desjardins Y, Levy E, Marette A. “A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice.” Gut. 2015 June; 64(6):872-83), Concord grape (Roopchand D E, Carmody R N, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh P J, Raskin I.
- a fecal microbiota transplantation method by which fecal matter from a person carrying Akkermansia muciniphila in the body is transplanted, is another possible method for increasing Akkermansia muciniphila ; however, the effectiveness of this method varies among individuals and moreover this method is not practical in terms of cost.
- the range of blood astaxanthin concentrations in the rodents was 0 to 1720 ng/ml (excluding 0), preferably 0 to 820 ng/ml (excluding 0), and more preferably 0 to 55 ng/ml (excluding 0).
- a human ingests 1 to 40 mg of astaxanthin per day for achieving the above-mentioned more preferable blood concentration.
- Astaxanthin that may be used in an embodiment of the present invention is not particularly limited and at least one of natural astaxanthin and synthetic astaxanthin may be used.
- Examples of the natural astaxanthin may include astaxanthin obtainable from an alga such as a Haematococcus alga; a yeast such as a Phaffia yeast; a crustacean such as a shrimp, a krill, and a crab; a cephalopod such as a squid and an octopus; various fishes and shellfishes; a plant such as an Adonis plant; a bacterium such as Paracoccus sp. N81106, Brevundimonas sp. SD212, and Erythrobacter sp. PC6; an actinomycete such as Gordonia sp.
- an alga such as a Haematococcus alga
- a yeast such as a Phaffia yeast
- a crustacean such as a shrimp, a krill, and a crab
- a cephalopod such as a squid and an octop
- KANMONKAZ-1129 a Labyrinthulomycetes such as Schizochytrium sp. KH105; and an organism genetically modified to produce astaxanthin.
- a preferable example may be astaxanthin extracted from a microalga such as a Haematococcus alga and a more preferable example may be astaxanthin extracted from a Haematococcus alga.
- Examples of the synthetic astaxanthin may include AstaSana (DSM) and Lucantin Pink® (BASF).
- Examples of the synthetic astaxanthin chemically converted from other naturally-occurring carotenoids may include AstaMarine (PIVEG, Inc.).
- Haematococcus alga from which natural astaxanthin is obtainable may include Haematococcus pluvialis, Haematococcus lacustris, Haematococcus capensis, Haematococcus droebakensis , and Haematococcus zimbabwiensis.
- a preferable method for culturing these Haematococcus algae is a culture method in an enclosed system, in which no contamination or growth of a different species of microorganism occurs and a low level of contamination by other foreign substances occurs.
- Examples of such a culture method may include a culture method by using a culture apparatus including a partially-open-type culture device in a domed, conical, or cylindrical shape and a gas jet unit freely movable within the device (International Publication No.
- WO 1999/050384 discloses a method including the steps of inducing encystment of a Haematococcus alga by applying drying-stress to it and collecting astaxanthin from the culture of the encysted Haematococcus alga
- a culture method by using an enclosed culture device with a light source placed therein, the light source emitting light internally
- a method by using a tabular fermenter or a tubular fermenter.
- Astaxanthin and/or the composition containing astaxanthin that can be used in an embodiment of the present invention may be, for example, astaxanthin obtained by crushing cell walls of the above-mentioned Haematococcus alga, if required, according to a method disclosed in, for example, Japanese Patent Laid-Open No. H05-068585; adding a solvent such as an organic solvent, for example, acetone, an ether, chloroform, and an alcohol (e.g., ethanol and methanol) and supercritical carbon dioxide; and performing extraction, and/or a composition containing such astaxanthin.
- the astaxanthin concentration in the composition containing astaxanthin is preferably 3 to 40% (w/w), more preferably 3 to 12% (w/w), and even more preferably 5 to 10% (w/w).
- examples of astaxanthin and/or the composition containing astaxanthin that can be used in an embodiment of the present invention can include a commercially available product.
- examples of such a commercially available product may include the ASTOTS series such as ASTOTS-S, ASTOTS-10O, ASTOTS-ECS, ASTPTS-2.0PW, and ASTOTS-3.0 MB (In all products, ASTOTS is a registered trademark.
- AstaReal, Astavita, and Astamate series such as AstaReal oil 50F, AstaReal oil 5F, AstaReal powder 20F, water-soluble AstaReal solution, AstaReal WS solution, AstaReal 10WS solution, AstaReal ACT, Astavita e, Astavita SPORTS, and Astamate (all are registered trademarks.
- a method for ingesting astaxanthin may be by consuming a supplement, a health food, a functional nutritional food, or the like, or a beverage supplemented with astaxanthin. Furthermore, another method for ingesting astaxanthin may be by administering astaxanthin as various pharmaceutical compositions such as a tablet, a capsule, a granule, a fine granule, and a liquid formulation.
- Akkermansia muciniphila
- IBS irritable bowel syndrome
- composition containing astaxanthin is useful as a pharmaceutical composition for ameliorating or preventing these symptoms.
- the analysis method included extracting DNA in the cecum contents, amplifying the V3-V4 region in a 16SrRNA gene, and performing sequencing.
- FIG. 1 shows that the bacterial strain that increased in the Asx group as compared with the control group was a bacterium of the genus Akkermansia and the number of the bacteria of the genus Akkermansia in the Asx group increased and was about 11.7 times higher than that of the control group.
- the bacterial strain that decreased in the Asx group as compared with the control group was Clostridia (decreased from 58.2% to 47.6%) and Lactobacillus (decreased from 10.9% to 5.9%).
- mice Twenty four-day-old Wistar rats (rodents) were used to compare the body weights of a group fed with a diet containing 0.02% astaxanthin (an Asx group) and the body weights of a group fed with a normal diet (a control group).
- FIG. 2( a ) shows the postnatal day (PND), body weights, and variation in body weights of the rats (rodents).
- FIG. 2( b ) shows an average body weight and an average increase of PND72,76.
- ingestion of the composition containing astaxanthin is effective for, for example, ameliorating a symptom of irritable bowel syndrome (IBS) and ameliorating or preventing obesity.
- IBS irritable bowel syndrome
- a blood astaxanthin concentration means an astaxanthin concentration in blood serum or blood plasma.
- This filtrate was concentrated by a centrifugal evaporator.
- the concentrate was redissolved in 150 ⁇ l of acetone and was subjected to reverse-phase HPLC.
- a standard solution was prepared by adding 2.5 ml of 800 ng/ml internal standard in acetone to 1 ml of 2 ⁇ g/ml astaxanthin (astaxanthin, ALEXIS BIOCHEMICALS, 460-031-M250) in acetone and adding acetone to make 20 ml, and was also subjected to reverse-phase HPLC.
- the blood astaxanthin concentration was calculated based on the peak area ratio of the above-mentioned two solutions obtained by HPLC.
- YMC-Carotenoid (4.6 ⁇ 250 mm, particle size: 5 ⁇ m) was used as an analytical column.
- the mobile phase included methanol as solvent A, tert-butyl methyl ether as solvent B, and 1% aqueous phosphate solution as solvent C.
- the mixing percentage of solvent C was consistently maintained at 4%.
- the temperature of the column oven was set at 25° C. and measurement was performed at a detection wavelength of 470 nm by using a UV/VIS detector.
- the flow rate of the mobile phase was set at 1 ml/min.
- the result of measurement of the astaxanthin concentration in rodent blood is shown in FIG. 3 .
- the range of the blood astaxanthin concentration was more than 0 and no more than 1720 ng/ml.
- a blood astaxanthin concentration means an astaxanthin concentration in blood serum or blood plasma.
- a blood astaxanthin concentration was measured by HPLC.
- This filtrate was concentrated by a centrifugal evaporator. Then, the concentrate was redissolved in 150 ⁇ l of acetone and was subjected to reverse-phase HPLC.
- a standard solution was prepared by adding 1 ml of 10 ⁇ g/ml internal standard (ethyl 8′-apo-beta-caroten-8′-oate) in acetone to 100 ml of 100 ng/ml astaxanthin (astaxanthin, ALEXIS BIOCHEMICALS, 460-031-M250) in acetone, and was also subjected to reverse-phase HPLC.
- the blood astaxanthin concentration was calculated based on the peak area ratio of the above-mentioned two solutions obtained by HPLC.
- YMC-Carotenoid (4.6 ⁇ 250 mm, particle size: 5 ⁇ m) was used as an analytical column.
- the mobile phase included methanol as solvent A, tert-butyl methyl ether as solvent B, and 1% aqueous phosphate solution as solvent C.
- Gradient elusion was performed so that the mixing ratio of solvent A and solvent B was 93%:5% when flowing of the mobile phase was started, and the mixing percentage of solvent B became 16% at 4 minutes, 22.5% at 7 minutes, 48.75% at 25.6 minutes, and 90% at 33.2 minutes.
- the mixing ratio was returned to the starting mixing ratio at 41.7 minutes and this starting mixing ratio was maintained until 53.4 minutes.
- the mixing percentage of solvent C was consistently maintained at 2%.
- the temperature of the column oven was set at 16° C. and measurement was performed at a detection wavelength of 470 nm by using a UV/VIS detector.
- the flow rate of the mobile phase was set at 1 ml/min.
- the range of the blood astaxanthin concentration was more than 0 and no more than 600 ng/ml.
- Blood collection was performed 1, 6, 13, 20, 27, 34, and 42 days after the first ingestion of the capsules to obtain blood plasma.
- the blood astaxanthin concentration was measured by the above-mentioned analytical method (HPLC).
- FIG. 4 shows the change in the astaxanthin concentration in human blood (in blood plasma) when astaxanthin was ingested for a long period.
- the present invention is effective for increasing bacteria belonging to the genus Akkermansia in an intestinal bacterial flora and astaxanthin can be ingested in various methods.
- Increase of the bacteria ( muciniphila ) belonging to the genus Akkermansia in the intestinal bacterial flora can allow for, for example, ameliorating a symptom of irritable bowel syndrome (IBS) and ameliorating or preventing obesity. Therefore, the present invention is also useful in ingestion as a pharmaceutical composition.
- IBS irritable bowel syndrome
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
A method for increasing bacteria belonging to the genus Akkermansia in an intestinal bacterial flora, comprising the step of ingesting a composition containing astaxanthin.
Description
- Japanese Patent Application No. 2018-17002 filed on Feb. 2, 2018, is hereby incorporated by reference in its entirety.
- This application is a continuation of U.S. patent application Ser. No. 15/946,783, filed Apr. 6, 2018, the entirety of which is incorporated herein by reference.
- The present invention relates to a method for improving bacteria belonging to the genus Akkermansia in an intestinal bacterial flora, and the like.
- The intestinal bacterial flora changes depending on factors such as living environment and is believed to have a great impact on, for example, health status.
- For example, irritable bowel syndrome (IBS) is a gastrointestinal dysfunction in which a symptom such as diarrhea, constipation, and abdominal pain occurs although no organic abnormalities such as inflammation and ulcer are found by an examination, and is considered to be a type of functional dyspepsia.
- Although the pathogenic mechanism of IBS is still unknown in many respects, attention has been drawn to correlation between central nervous function and gastrointestinal function, specifically, gut-brain interaction and hypersensitive gastrointestinal tract in the context of psychological stress.
- Some enterobacteria greatly influence obesity and a disease associated therewith.
- As is detailed below, it is reported that Akkermansia muciniphila enterobacteria are associated with obesity and a disease associated therewith.
- The present inventors investigated how astaxanthin influenced the intestinal bacterial flora and consequently accomplished the present invention.
- Japanese Patent Laid-Open No. H09-124470 discloses an anti-stress composition containing astaxanthin and/or an ester thereof as an active ingredient; however it does not disclose the influence of the composition on the intestinal bacterial flora in any way.
- A feature of an aspect of the present invention is inclusion of a step of ingesting a composition containing astaxanthin.
- According to this feature, it is possible to increase bacteria belonging to the genus Akkermansia in an intestinal bacterial flora.
-
FIG. 1 shows the result of comparison of intestinal bacterial floras; -
FIGS. 2A and 2B show the result of a comparative study of increases in body weight; -
FIG. 3 shows comparison of blood astaxanthin concentrations between a rodent and a human; and -
FIG. 4A shows the change in the astaxanthin concentration in human blood caused by continuous ingestion of astaxanthin; andFIG. 4B shows the measured data. - It is an object of the present invention to improve the balance of an intestinal bacterial flora, in particular, to increase bacteria belonging to the genus Akkermansia.
- An embodiment of the present invention includes the step of ingesting a composition containing astaxanthin for increasing bacteria belonging to the genus Akkermansia in the intestinal bacterial flora, preferably Akkermansia muciniphila among others.
- Astaxanthin is a type of carotenoid. Carotenoids are classified into carotenes and xanthophylls, and astaxanthin belongs to the xanthophyll group.
- The IUPAC name of astaxanthin is 3,3′-dihydroxy-β,β-carotene-4,4′-dione and there are three forms of astaxanthin depending on the configurations of the hydroxy groups at 3 and 3′ positions: a (3R,3′R) form, a (3R,3′S) form, and a (3S,3′S) form.
- Astaxanthin also has isomers defined by a cis-trans orientation around a conjugated double bond, and exists in a free form, a monoesterified form, or a diesterified form.
- Astaxanthin is known to have an antioxidative activity and it has low absorption efficiency, with its absorption percentage in the intestine being about 5%.
- It is presumed from this fact that about 95% of astaxanthin is not absorbed and remains in the intestine, and directly acts on the intestinal bacterial flora.
- Thus, as detailed below, 6-week-old Wistar rats (rodents) were used to compare the intestinal bacterial floras of a group fed with an astaxanthin-containing diet for four weeks and a group fed with a normal diet for four weeks. It is presumed from the result that the number of Akkermansia muciniphila, bacteria of the genus Akkermansia, in the group fed with the astaxanthin-containing diet increased and is about 11.7 times higher than that of the group fed with the normal diet.
- Articles reported so far were reviewed and polyphenols such as Capsaicin (Shen W, Shen M, Zhao X, Zhu H, Yang Y, Lu S, Tan Y, Li G, Li M, Wang J, Hu F, Le S. “Anti-obesity Effect of Capsaicin in Mice Fed with High-Fat Diet Is Associated with an Increase in Population of the Gut Bacterium Akkermansia muciniphila.” Front Microbiol. 2017 Feb. 23; 8), saponin (Leal-Diaz A M, Noriega L G, Torre-Villalvazo I, Torres N, Aleman-Escondrillas G, Lopez-Romero P, Sanchez-Tapia M, Aguilar-Lopez M, Furuzawa-Carballeda J, Velazquez-Villegas L A, Avila-Nava A, Ordaz G, Gutierrez-Uribe J A, Serna-Saldivar S O, Tovar A R. “Aguamie concentrate from Agave salmiana and its extracted saponins attenuated obesity and hepatic steatosis and increased Akkermansia muciniphila in C57BL6 mice.” Sci Rep. 2016 Sep. 28; 6:34242), Procyanidin (Masumoto S, Terao A, Yamamoto Y, Mukai T, Miura T, Shoji T. “Non-absorbable apple procyanidins prevent obesity associated with gut microbial and metabolomic changes.” Sci Rep. 2016 Aug. 10; 6:31208), Cranberry extract (Anhe F F, Roy D, Pilon G, Dudonne S, Matamoros S, Varin T V, Garofalo C, Moine Q, Desjardins Y, Levy E, Marette A. “A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice.” Gut. 2015 June; 64(6):872-83), Concord grape (Roopchand D E, Carmody R N, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh P J, Raskin I. “Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome.” Diabetes. 2015 August; 64(8):2847-58) had been reported to show an effect of increasing Akkermansia muciniphila. However, polyphenol is reported to be degraded by enterobacteria, and therefore is disadvantageous for improvement of the intestinal bacterial flora and safety (Peng X, Zhang Z, Zhang N, Li S, Wei H. “In vitro catabolism of quercetin by human fecal bacteria and the antioxidant capacity of its catabolites.” Food Nutr Res. 2014 Apr. 15; 58, Noguchi N, Ohashi T, Shiratori T, Narui K, Hagiwara T, Ko M, Watanabe K, Miyahara T, Taira S, Moriyasu F, Sasatsu M. “Association of tannase-producing Staphylococcus lugdunensis with colon cancer and characterization of a novel tannase gene.” J Gastroenterol. 2007 May; 42(5):346-51).
- A fecal microbiota transplantation method, by which fecal matter from a person carrying Akkermansia muciniphila in the body is transplanted, is another possible method for increasing Akkermansia muciniphila; however, the effectiveness of this method varies among individuals and moreover this method is not practical in terms of cost.
- The below-mentioned study result indicated that the range of blood astaxanthin concentrations in the rodents was 0 to 1720 ng/ml (excluding 0), preferably 0 to 820 ng/ml (excluding 0), and more preferably 0 to 55 ng/ml (excluding 0).
- It is preferable that a human ingests 1 to 40 mg of astaxanthin per day for achieving the above-mentioned more preferable blood concentration.
- When a human ingested 1 to 60 mg of astaxanthin per day, the range of its blood concentration was more than 0 and no more than 600 ng/ml.
- Astaxanthin that may be used in an embodiment of the present invention is not particularly limited and at least one of natural astaxanthin and synthetic astaxanthin may be used.
- Examples of the natural astaxanthin may include astaxanthin obtainable from an alga such as a Haematococcus alga; a yeast such as a Phaffia yeast; a crustacean such as a shrimp, a krill, and a crab; a cephalopod such as a squid and an octopus; various fishes and shellfishes; a plant such as an Adonis plant; a bacterium such as Paracoccus sp. N81106, Brevundimonas sp. SD212, and Erythrobacter sp. PC6; an actinomycete such as Gordonia sp. KANMONKAZ-1129; a Labyrinthulomycetes such as Schizochytrium sp. KH105; and an organism genetically modified to produce astaxanthin. A preferable example may be astaxanthin extracted from a microalga such as a Haematococcus alga and a more preferable example may be astaxanthin extracted from a Haematococcus alga. Examples of the synthetic astaxanthin may include AstaSana (DSM) and Lucantin Pink® (BASF). Examples of the synthetic astaxanthin chemically converted from other naturally-occurring carotenoids may include AstaMarine (PIVEG, Inc.).
- Examples of the Haematococcus alga from which natural astaxanthin is obtainable may include Haematococcus pluvialis, Haematococcus lacustris, Haematococcus capensis, Haematococcus droebakensis, and Haematococcus zimbabwiensis.
- A preferable method for culturing these Haematococcus algae is a culture method in an enclosed system, in which no contamination or growth of a different species of microorganism occurs and a low level of contamination by other foreign substances occurs. Examples of such a culture method may include a culture method by using a culture apparatus including a partially-open-type culture device in a domed, conical, or cylindrical shape and a gas jet unit freely movable within the device (International Publication No. WO 1999/050384); and a method including the steps of inducing encystment of a Haematococcus alga by applying drying-stress to it and collecting astaxanthin from the culture of the encysted Haematococcus alga (Japanese Patent Laid-Open No. H08-103288); a culture method by using an enclosed culture device with a light source placed therein, the light source emitting light internally; and a method by using a tabular fermenter or a tubular fermenter.
- Astaxanthin and/or the composition containing astaxanthin that can be used in an embodiment of the present invention may be, for example, astaxanthin obtained by crushing cell walls of the above-mentioned Haematococcus alga, if required, according to a method disclosed in, for example, Japanese Patent Laid-Open No. H05-068585; adding a solvent such as an organic solvent, for example, acetone, an ether, chloroform, and an alcohol (e.g., ethanol and methanol) and supercritical carbon dioxide; and performing extraction, and/or a composition containing such astaxanthin. In this case, the astaxanthin concentration in the composition containing astaxanthin is preferably 3 to 40% (w/w), more preferably 3 to 12% (w/w), and even more preferably 5 to 10% (w/w).
- Furthermore, examples of astaxanthin and/or the composition containing astaxanthin that can be used in an embodiment of the present invention can include a commercially available product. Examples of such a commercially available product may include the ASTOTS series such as ASTOTS-S, ASTOTS-10O, ASTOTS-ECS, ASTPTS-2.0PW, and ASTOTS-3.0 MB (In all products, ASTOTS is a registered trademark. Fujifilm Corporation); the AstaReal, Astavita, and Astamate series, such as AstaReal oil 50F, AstaReal oil 5F, AstaReal powder 20F, water-soluble AstaReal solution, AstaReal WS solution, AstaReal 10WS solution, AstaReal ACT, Astavita e, Astavita SPORTS, and Astamate (all are registered trademarks. AstaReal Co., Ltd., Fuji Chemical Industry Co, Ltd.); BioAstin®, Cyanotech Corporation); Astazine™ (BGG Japan Co., Ltd.); astaxanthin powder 1.5%, astaxanthin powder 2.5%,
astaxanthin oil 5%,astaxanthin oil 10% (Bio Actives Japan Corporation.); astaxanthin (Oryza Oil&Fat Chemical Co., Ltd.); SunActive AX® (Taiyo Kagaku Co., Ltd.); Haematococcus WS30 (YAEGAKI Bio-industry, Inc.); and AstaMarine (Piveg, Inc.). - A method for ingesting astaxanthin may be by consuming a supplement, a health food, a functional nutritional food, or the like, or a beverage supplemented with astaxanthin. Furthermore, another method for ingesting astaxanthin may be by administering astaxanthin as various pharmaceutical compositions such as a tablet, a capsule, a granule, a fine granule, and a liquid formulation.
- Ingestion of the composition containing astaxanthin as described above leads to increase of Akkermansia (muciniphila) in the intestinal bacterial flora and thereby allows for, for example, ameliorating a symptom of irritable bowel syndrome (IBS) and ameliorating or preventing obesity.
- Therefore, the composition containing astaxanthin is useful as a pharmaceutical composition for ameliorating or preventing these symptoms.
- Six-week-old Wistar rats (rodents) were used to compare the intestinal bacterial flora of a group fed with a diet containing 0.02% astaxanthin (an Asx group) and the intestinal bacterial flora of a group fed with a normal diet (a control group).
- Saline or corticotropin-releasing hormone (CRH) was intravenously administered to the rats after feeding each group with each corresponding diet for four weeks.
- Three hours after administration, the rats were sacrificed and the intestinal bacterial floras in the cecum contents of each group were analyzed and compared. The result is shown in the graph of
FIG. 1 . - The analysis method included extracting DNA in the cecum contents, amplifying the V3-V4 region in a 16SrRNA gene, and performing sequencing.
-
FIG. 1 shows that the bacterial strain that increased in the Asx group as compared with the control group was a bacterium of the genus Akkermansia and the number of the bacteria of the genus Akkermansia in the Asx group increased and was about 11.7 times higher than that of the control group. - The bacterial strain that decreased in the Asx group as compared with the control group was Clostridia (decreased from 58.2% to 47.6%) and Lactobacillus (decreased from 10.9% to 5.9%).
- Furthermore, enhancement of intestinal peristaltic movement induced by administration of CRH was reduced in the Asx group.
- Therefore, it is presumed that ingestion of the composition containing astaxanthin produces an effect of increasing the proportion of Akkermansia muciniphila belonging to the genus Akkermansia in the intestinal bacterial flora by a factor of about 10 or more.
- Twenty four-day-old Wistar rats (rodents) were used to compare the body weights of a group fed with a diet containing 0.02% astaxanthin (an Asx group) and the body weights of a group fed with a normal diet (a control group).
- The table in
FIG. 2(a) shows the postnatal day (PND), body weights, and variation in body weights of the rats (rodents).FIG. 2(b) shows an average body weight and an average increase of PND72,76. - The result shows that increase in body weight was clearly less in the Asx group.
- Therefore, it is presumed that ingestion of the composition containing astaxanthin is effective for, for example, ameliorating a symptom of irritable bowel syndrome (IBS) and ameliorating or preventing obesity.
- Next, an astaxanthin concentration in rodent blood was investigated.
- In this context, a blood astaxanthin concentration means an astaxanthin concentration in blood serum or blood plasma.
- A study was performed as follows: a mouse or a rat (a rodent) was fed with a diet containing 0.02% astaxanthin for about one month and blood was collected to obtain blood serum or blood plasma; and a blood astaxanthin concentration was measured by HPLC.
- Analysis was performed as follows:
- Five hundred microliters of 50 μg/ml butylhydroxytoluene in ethanol and 100 of 100 ng/ml internal standard (trans-β-Apo-8′-carotenal) in acetone were added to 100 μl of the obtained blood serum or blood plasma sample, and the mixture was stirred vigorously for 15 seconds by a vortex mixer.
- Furthermore, 5 ml of hexane was added to the blood serum or blood plasma, and subsequently the mixture was stirred vigorously for 15 seconds by the vortex mixer three times and centrifuged at 3500 rpm for 10 minutes.
- Four milliliters of the supernatant after centrifugation was collected and filtrated through a membrane filter with a mesh size of 0.45 μm.
- This filtrate was concentrated by a centrifugal evaporator.
- Then, the concentrate was redissolved in 150 μl of acetone and was subjected to reverse-phase HPLC.
- In parallel, a standard solution was prepared by adding 2.5 ml of 800 ng/ml internal standard in acetone to 1 ml of 2 μg/ml astaxanthin (astaxanthin, ALEXIS BIOCHEMICALS, 460-031-M250) in acetone and adding acetone to make 20 ml, and was also subjected to reverse-phase HPLC.
- The blood astaxanthin concentration was calculated based on the peak area ratio of the above-mentioned two solutions obtained by HPLC.
- Shimadzu LC-20A series (pump: LC-20AD, degasser: DGU-20A5R, autosampler: SIL-20AC, column oven: CTO-20AC, detector: SPD-20AV, system controller: CBM-20A) were used for HPLC.
- YMC-Carotenoid (4.6×250 mm, particle size: 5 μm) was used as an analytical column.
- The mobile phase included methanol as solvent A, tert-butyl methyl ether as solvent B, and 1% aqueous phosphate solution as solvent C.
- Gradient elusion was performed so that the mixing ratio of solvent A and solvent B was 81%:15% when flowing of the mobile phase was started, and the mixing percentage of solvent B became 30% at 15 minutes and 80% at 23 minutes. After maintaining the mixing percentage of solvent B at 80% until 27 minutes, the mixing ratio was returned to the starting mixing ratio at 27.1 minutes and this starting mixing ratio was maintained until 35 minutes.
- The mixing percentage of solvent C was consistently maintained at 4%.
- The temperature of the column oven was set at 25° C. and measurement was performed at a detection wavelength of 470 nm by using a UV/VIS detector.
- The flow rate of the mobile phase was set at 1 ml/min.
- The result of measurement of the astaxanthin concentration in rodent blood is shown in
FIG. 3 . - When the mouse or the rat was fed with the diet containing 0.02% astaxanthin for about one month, the range of the blood astaxanthin concentration was more than 0 and no more than 1720 ng/ml.
- Next, an astaxanthin concentration in human blood was investigated.
- In this context, a blood astaxanthin concentration means an astaxanthin concentration in blood serum or blood plasma.
- A blood astaxanthin concentration was measured by HPLC.
- Analysis was performed as follows:
- Five hundred microliters of 50 μg/ml butylhydroxytoluene in ethanol, 100 μl of 100 ng/ml internal standard (
ethyl 8′-apo-beta-caroten-8′-oate, Carote Nature, 1010) in acetone, and 500 μl of distilled water were added to 100 μl of the obtained blood serum or blood plasma sample, and the mixture was stirred vigorously for 15 seconds by a vortex mixer. - Furthermore, 5 ml of hexane was added to the blood serum or blood plasma, and subsequently the mixture was stirred vigorously for 15 seconds by the vortex mixer three times and centrifuged at 3500 rpm for 10 minutes.
- Four milliliters of the supernatant after centrifugation was collected and filtrated through a membrane filter with a mesh size of 0.45 μm.
- This filtrate was concentrated by a centrifugal evaporator. Then, the concentrate was redissolved in 150 μl of acetone and was subjected to reverse-phase HPLC.
- In parallel, a standard solution was prepared by adding 1 ml of 10 μg/ml internal standard (
ethyl 8′-apo-beta-caroten-8′-oate) in acetone to 100 ml of 100 ng/ml astaxanthin (astaxanthin, ALEXIS BIOCHEMICALS, 460-031-M250) in acetone, and was also subjected to reverse-phase HPLC. The blood astaxanthin concentration was calculated based on the peak area ratio of the above-mentioned two solutions obtained by HPLC. - Shimadzu LC-20A series (pump: LC-20AD, degasser: DGU-20A5R, autosampler: SIL-20AC, column oven: CTO-20AC, detector: SPD-20AV, system controller: CBM-20A) were used for HPLC.
- YMC-Carotenoid (4.6×250 mm, particle size: 5 μm) was used as an analytical column.
- The mobile phase included methanol as solvent A, tert-butyl methyl ether as solvent B, and 1% aqueous phosphate solution as solvent C. Gradient elusion was performed so that the mixing ratio of solvent A and solvent B was 93%:5% when flowing of the mobile phase was started, and the mixing percentage of solvent B became 16% at 4 minutes, 22.5% at 7 minutes, 48.75% at 25.6 minutes, and 90% at 33.2 minutes. After maintaining the mixing percentage of solvent B at 90% until 41.5 minutes, the mixing ratio was returned to the starting mixing ratio at 41.7 minutes and this starting mixing ratio was maintained until 53.4 minutes.
- The mixing percentage of solvent C was consistently maintained at 2%.
- The temperature of the column oven was set at 16° C. and measurement was performed at a detection wavelength of 470 nm by using a UV/VIS detector.
- The flow rate of the mobile phase was set at 1 ml/min.
- The results of measurement of the astaxanthin concentration in rodent blood and human blood are shown in
FIG. 3 . - When a human received 1 to 60 mg of astaxanthin per day, the range of the blood astaxanthin concentration was more than 0 and no more than 600 ng/ml.
- As the astaxanthin concentrations in rodent blood and human blood are found to be correlated to some extent, it is presumed that the above-mentioned effect of increasing Akkermansia muciniphila in a Wistar rat resulting from administration of astaxanthin is also observed in a human.
- Next, a test on humans was performed to monitor how an astaxanthin concentration in blood (in blood plasma) changed when astaxanthin was ingested for a long period. A study was performed as follows:
- Ten healthy Japanese males and females aged 20 years or older and younger than 50 years
- The subjects ingested two capsules per day (equivalent to 12 mg/day astaxanthin in free form) together with
water 30 minutes after breakfast for 42 days, with one capsule containing 60 mg of Haematococcus alga extract (equivalent to 6 mg of astaxanthin in free form) and 270 mg of edible oil and fat. - Blood collection was performed 1, 6, 13, 20, 27, 34, and 42 days after the first ingestion of the capsules to obtain blood plasma. The blood astaxanthin concentration was measured by the above-mentioned analytical method (HPLC).
-
FIG. 4 shows the change in the astaxanthin concentration in human blood (in blood plasma) when astaxanthin was ingested for a long period. - As is shown in
FIG. 4 , when the subject consumed two units of food (capsules) per day for 42 days, with one unit containing 60 mg of Haematococcus alga extract (equivalent to 6 mg of astaxanthin in free form) and 270 mg of edible oil and fat, it was found that the astaxanthin concentration in human blood (in blood plasma) started to plateau around 200 ng/ml when about 6 days passed after the beginning of ingestion. These results revealed that the astaxanthin concentration in human blood (in blood plasma) did not decrease as long as the subject at least continued to consume the food containing astaxanthin. - The present invention is effective for increasing bacteria belonging to the genus Akkermansia in an intestinal bacterial flora and astaxanthin can be ingested in various methods. Increase of the bacteria (muciniphila) belonging to the genus Akkermansia in the intestinal bacterial flora can allow for, for example, ameliorating a symptom of irritable bowel syndrome (IBS) and ameliorating or preventing obesity. Therefore, the present invention is also useful in ingestion as a pharmaceutical composition.
- Although only some embodiments of the present invention have been described in detail above, those skilled in the art will readily appreciate that many modifications are possible in the embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within scope of this invention.
Claims (6)
1. A method of increasing a percentage of bacteria belonging to the genus Akkermansia in an intestinal bacterial flora, and decreasing a percentage of at least bacteria belonging to Clostridia and Lactobacillus in the intestinal bacterial flora, in a patient in need of such an increase and such a decrease, the method comprising administering to such a patient a composition containing astaxanthin, wherein a daily amount of said astaxanthin administered is 1 to 40 mg.
2. The method of claim 1 , wherein said bacteria belonging to the genus Akkermansia are Akkermansia muciniphila.
3. The method of claim 1 , wherein said composition containing astaxanthin is administered so that a blood astaxanthin concentration becomes more than 0 and no more than 600 ng/ml.
4. The method of claim 1 , wherein said composition containing astaxanthin is ingested for ameliorating a symptom of irritable bowel syndrome (IBS).
5. The method of claim 1 , wherein said daily amount of said astaxanthin is 1 to 2 mg.
6. The method of claim 1 , wherein said daily amount of said astaxanthin is 6 to 40 mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/080,118 US20210052516A1 (en) | 2018-02-02 | 2020-10-26 | Method for increasing akkermansia in intestinal bacterial flora by ingesting astaxanthin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-017002 | 2018-02-02 | ||
JP2018017002A JP7352237B2 (en) | 2018-02-02 | 2018-02-02 | Method and pharmaceutical composition of using astaxanthin to increase Akkermansia in intestinal flora |
US15/946,783 US10894022B2 (en) | 2018-02-02 | 2018-04-06 | Method for increasing Akkermansia in intestinal bacterial flora by ingesting astaxanthin |
US17/080,118 US20210052516A1 (en) | 2018-02-02 | 2020-10-26 | Method for increasing akkermansia in intestinal bacterial flora by ingesting astaxanthin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/946,783 Continuation US10894022B2 (en) | 2018-02-02 | 2018-04-06 | Method for increasing Akkermansia in intestinal bacterial flora by ingesting astaxanthin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210052516A1 true US20210052516A1 (en) | 2021-02-25 |
Family
ID=67476326
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/946,783 Active US10894022B2 (en) | 2018-02-02 | 2018-04-06 | Method for increasing Akkermansia in intestinal bacterial flora by ingesting astaxanthin |
US17/080,118 Abandoned US20210052516A1 (en) | 2018-02-02 | 2020-10-26 | Method for increasing akkermansia in intestinal bacterial flora by ingesting astaxanthin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/946,783 Active US10894022B2 (en) | 2018-02-02 | 2018-04-06 | Method for increasing Akkermansia in intestinal bacterial flora by ingesting astaxanthin |
Country Status (2)
Country | Link |
---|---|
US (2) | US10894022B2 (en) |
JP (2) | JP7352237B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021045138A1 (en) * | 2019-09-04 | 2021-03-11 | Eneos株式会社 | Composition for improving irritable bowel syndrome |
CN115433703B (en) * | 2022-10-27 | 2023-03-24 | 中国农业大学 | Application of capsaicin in promoting proliferation of akkermansia muciniphila |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3725189B2 (en) | 1994-10-03 | 2005-12-07 | ヒガシマル醤油株式会社 | Method for producing astaxanthin and astaxanthin-containing material |
JPH09124470A (en) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | Antistress composition |
US6348347B1 (en) | 1998-03-31 | 2002-02-19 | Micro Gaia Co., Ltd. | Fine algae culture device |
JP2007238441A (en) * | 2004-12-03 | 2007-09-20 | Fuji Chem Ind Co Ltd | Composition for body fat reduction containing astaxanthin as active ingredient |
JP2007099715A (en) * | 2005-10-06 | 2007-04-19 | Yoshihiro Futamura | Alliin fatty acid conjugate showing neutral fat-reducing effect, and food preparation, cosmetic and anti-obesity agent consisting of the same |
JP2007153846A (en) | 2005-12-07 | 2007-06-21 | Yamaha Motor Co Ltd | Diabetes-preventing agent |
EP2163252A4 (en) * | 2007-05-17 | 2012-01-11 | Kaneka Corp | Composition containing licorice-derived polyphenol |
JP2009019005A (en) * | 2007-07-11 | 2009-01-29 | Yamaha Motor Co Ltd | Lipolysis promoter |
JP2012072132A (en) * | 2010-08-31 | 2012-04-12 | Fuji Chem Ind Co Ltd | Life-extending agent |
JPWO2014208511A1 (en) | 2013-06-27 | 2017-02-23 | 学校法人同志社 | Composition for improving intestinal flora containing astaxanthin |
WO2015137500A1 (en) * | 2014-03-14 | 2015-09-17 | 富士化学工業 株式会社 | Anti-obesity agent |
JP2018534277A (en) * | 2015-10-05 | 2018-11-22 | シュヴァイツェリッシェ フォルシュングスインスティテュート フュア ホーフゲブリクスクリーマ ウント メディツィン イン ダヴォス | Use of Akkermansia muciniphila for treating inflammatory conditions |
WO2017213176A1 (en) * | 2016-06-08 | 2017-12-14 | アスタリール株式会社 | Food or beverage composition containing astaxanthin |
-
2018
- 2018-02-02 JP JP2018017002A patent/JP7352237B2/en active Active
- 2018-04-06 US US15/946,783 patent/US10894022B2/en active Active
-
2020
- 2020-10-26 US US17/080,118 patent/US20210052516A1/en not_active Abandoned
-
2022
- 2022-01-17 JP JP2022004914A patent/JP2022043349A/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
Webpage printout of https://web.archive.org/web/20160304101027/http://drohhiraprobiotics.com/dr-ohhira-propolis-plus-1-box-60-capsules-on-sale, captured March 4, 2016, as evidenced by the Internet Archive Wayback Machine, pp.1-3. (Year: 2016) * |
Webpage printout of https://www.crohns.net/blog/post/irritable-bowel-syndrome-ibs, dated 6/14/2017, pp.1-2. (Year: 2017) * |
Also Published As
Publication number | Publication date |
---|---|
JP2022043349A (en) | 2022-03-15 |
JP7352237B2 (en) | 2023-09-28 |
US20190240168A1 (en) | 2019-08-08 |
US10894022B2 (en) | 2021-01-19 |
JP2019131527A (en) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Synergic interactions between polyphenols and gut microbiota in mitigating inflammatory bowel diseases | |
Yang et al. | Sinapic acid and resveratrol alleviate oxidative stress with modulation of gut microbiota in high-fat diet-fed rats | |
Yin et al. | Gut microbiota, dietary phytochemicals, and benefits to human health | |
US20210052516A1 (en) | Method for increasing akkermansia in intestinal bacterial flora by ingesting astaxanthin | |
Qaid et al. | Anticoccidial effectivity of a traditional medicinal plant, Cinnamomum verum, in broiler chickens infected with Eimeria tenella | |
CN110636760B (en) | Composition for promoting intestinal health | |
JPH07506837A (en) | High cis-β-carotene composition | |
RU2759600C2 (en) | Use of carotenoid of microbial origin that affects composition of intestinal microorganisms | |
Kan et al. | Polyphenolic-enriched peach peels extract regulates lipid metabolism and improves the gut microbiota composition in high fat diet-fed mice | |
Guo et al. | Probiotic-fermented Chinese dwarf cherry [Cerasus humilis (Bge.) Sok.] juice modulates the intestinal mucosal barrier and increases the abundance of Akkermansia in the gut in association with polyphenols | |
JP2017132748A (en) | Antistress active substances extracted from oyster meat | |
Yan et al. | Effect of fermented bee pollen on metabolic syndrome in high-fat diet-induced mice | |
Zhu et al. | The phytonutrient cinnamaldehyde limits intestinal inflammation and enteric parasite infection | |
de Oliveira Araújo et al. | Bacupari (Garcinia brasiliensis) extract modulates intestinal microbiota and reduces oxidative stress and inflammation in obese rats | |
Keirns et al. | Phytochemicals affect T helper 17 and T regulatory cells and gut integrity: implications on the gut-bone axis | |
Yilmaz et al. | Effects of dietary walnut (Juglans regia) leaves extract on immunity, gene expression responses, and disease resistance in Oreochromis niloticus | |
Liu et al. | Effect of nanoemulsion loading finger citron (Citrus medica L. var. Sarcodactylis) essential oil on human gut microbiota | |
Liu et al. | Analysis of the effects of Rosa roxburghii Tratt fruit polyphenols on immune function in mice through gut microbiota and metabolomics: An in vivo preclinical trial study | |
Li et al. | Safety assessment of desaminotyrosine: Acute, subchronic oral toxicity, and its effects on intestinal microbiota in rats | |
Santos et al. | Antibacterial activity of crude ethanolic and fractionated extracts of Punica granatum Linn. fruit peels | |
JP5070040B2 (en) | Vascular insufficiency improving agent | |
Song et al. | Comparison of the effects of chlorogenic acid isomers and their compounds on alleviating oxidative stress injury in broilers | |
Gao et al. | The improvement effect of astaxanthin-loaded emulsions on obesity is better than that of astaxanthin in the oil phase | |
JP2009196967A (en) | Agent for increasing relative quantity of polyunsaturated fatty acid in blood, and pharmaceutical composition, quasi-drug, cosmetics, edible composition and animal feed containing the agent | |
AT13888U1 (en) | Additive to feed, food, drinking water or pharmaceutical preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |